New Collection on TRACERx

The TRACERx project was set up in 2014 and aims to integrate new technologies to study cancer evolution in lung cancer patients.
Published in Cancer
New Collection on TRACERx
Like

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

The Tracking Lung Cancer Evolution through Therapy/Rx (TRACERx) lung study brings together a network of experts from across clinical and scientific disciplines and from research centres and hospitals around the UK. 

The 9-year programme is led by Professor Charles Swanton (UCL/Francis Crick) and funded by Cancer Research UK. The project aims to collect comprehensive genomic and clinical data from hundreds of non-small cell lung cancer (NSCLC) patients.

TRACERx is the first study to look at the evolution of cancer in real time and immense detail. Using cutting edge analytical techniques and following patients from diagnosis to either cure or relapse, researchers can investigate the genomic landscape of NSCLC, and how tumours evolve, metastasise and develop resistance.

Today, a collection of the latest findings is published by Nature.


Poster image: Lung cancer cells. Credit: Anne Weston, Francis Crick Institute.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in